Toxoplasma Gondii
Morphology | Obligate intracellular parasitic protozoa |
---|---|
Disease |
Typically, non-pathogenic in immunocompetent adults but can be severe in immunocompromised people. Can cause acute infection, retinochoroiditis, encephalitis, and congenital infection. |
Zoonosis |
Yes, from direct or indirect exposure of mucous membranes to oocysts of infected animals. Humans are intermediate hosts. |
Host Range | Cats and other felines, humans, mammals, birds, flies and cockroaches. |
---|---|
Modes of Transmission | Ingestion of contaminated food, water, and contaminated milk. Inhalation of aerosols containing oocysts. |
Signs and Symptoms | Symptoms include fever, rash, headache, lymphadenopathy, organomegaly, weight loss, weakness, pneumonia, and myalgia. |
Infectious Dose | Unknown |
Incubation Period | Unknown |
Prophylaxis | A treatment of sulfadiazine-pyrimethamine and folinic acid. |
---|---|
Vaccines | None available. |
Treatment | Antibiotic therapy spiramycin, sulfadiazine, and folinic acid. |
Surveillance | Monitor for symptoms and confirm by positive serology for antibodies. |
MSU Requirements | Report any exposures |
Laboratory Acquired Infections (LAIs) | 47 cases have been reported with one death. |
---|---|
Sources | May be present in blood, saliva, sputum, urine, milk, feces, and tissue. Cultures, frozen stocks, other samples described in IBC protocol. |
Canadian MSDS | http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/index-eng.php |
---|---|
BMBL
|
https://www.cdc.gov/labs/bmbl/?CDC_AAref_Val=https://www.cdc.gov/labs/BMBL.html |
CDC | https://www.cdc.gov/parasites/toxoplasmosis/index.html |
NIH Guidelines | https://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf |
Risk Group 2
|
Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available. |
---|---|
BSL2
|
For all procedures involving suspected or known infectious specimen or cultures.
|
ABSL2
|
For all procedures utilizing infected animals.
|
Small
|
Notify others working in the lab. Remove PPE and don new PPE. Cover area of the spill
with absorbent material and add fresh 1:10 bleach:water. Allow 20 munutes (or as directed)
of contact time. After 20 minutes, cleanup and dispose of materials.
|
---|---|
Large
|
|
Mucous membrane
|
Flush eyes, mouth, or nose for 5 minutes at eyewash station.
|
---|---|
Other Exposures
|
Wash area with soap and water for 5 minutes.
|
Reporting |
Immediately report incident to supervisor, complete a First Report of Injury form, and submit to Safety and Risk Management.
|
Medical Follow-up
|
During business hours: Bridger Occupational Health 3406 Laramie Drive. Weekdays 8am -6pm. Weekends 9am-5pm
After business hours: Bozeman Deaconess Hospital Emergency Room 915 Highland Blvd Bozeman, MT |
Disinfection | Susceptible to 1:10 bleach:water, 70 % ethanol and 10% formalin |
---|---|
Inactivation | Inactivated by moist heat (15 minutes at 121° C) and dry heat (1 hour at 160-170° C), short wave UV, and gamma irradiation. |
Survival Outside Host | Can survive in moist soil or water for up to 18 months. |
Minimum PPE Requirements
|
Lab coat, disposable gloves, safety glasses, closed toed shoes, long pants
|
---|---|
Additional Precautions
|
Additioanl PPE may be required depending on lab specific SOPs and IBC Protocol. |